Search results
Results from the WOW.Com Content Network
Cancer Immunology, Immunotherapy is a monthly peer-reviewed medical journal published by Springer Science+Business Media. According to the Journal Citation Reports , the journal has a 2020 impact factor of 6.968.
Cancer Immunology Research is a monthly peer-reviewed medical journal published by the American Association for Cancer Research. It covers research and clinical trials related to the study of cancer immunology. The editors-in-chief are Robert D. Schreiber and Philip Greenberg. [1] The journal was established in 2013. [1]
It was established in 2006 and is published nine times per year by Elsevier on behalf of the International Association for the Study of Lung Cancer, of which it is the official journal. The editor-in-chief is Alex Adjei (Roswell Park Comprehensive Cancer Center). According to the Journal Citation Reports, the journal has a 2018 impact factor of ...
It covers all areas of clinical oncology and experimental cancer research and publishes review articles, original articles, and editorials. It is published by e-Century Publishing Corporation. The editor-in-chief is Dr. Mien-Chie Hung. [1] [2] The journal is abstracted and indexed in the Science Citation Index Expanded. [4]
Cancer Cell is internationally regarded as one of the top cancer research and oncology journals. According to the Journal Citation Reports, the 2022 impact factor of the journal is 50.3. It is part of the Cell Press portfolio, which is owned by Elsevier. Issues are published monthly in print and online versions.
Issues are released monthly print and online (by Highwire Press), and an annual Index is also published. Anticancer Research was established in 1981 by John G. Delinassios. According to the Journal Citation Reports, the journal had a 2020 impact factor of 2.480 and 25,656 total cites. The 2020 rejection rate was 68%.
Immunotherapy is a peer-reviewed medical journal covering immunology and more specifically immunotherapy. It was established in 2009 and is published by Future Medicine. The founding editor-in-chief was Duc Hong Le. The current editors-in-chief are Y. Kawakami, F.M. Marincola, K. Tsang and D.C. Wraith.
Immunotherapy is designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies. Immunotherapy is under preliminary research for its potential to treat various forms of cancer. [1] [2] [3] [4]